MedPath

Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome

Phase 4
Conditions
Periodontal Inflammation
Periodontal Diseases
Microbial Colonization
Interventions
Registration Number
NCT04580355
Lead Sponsor
University of Campinas, Brazil
Brief Summary

Periodontitis is an inflammatory disease characterized by a dysbiotic microbiome which can lead to bone destruction and tooth loss. Several studies had been reported the association to periodontal disease with systemic conditions and this relation suggests and axis that links oral and gut microbiome. In order to clarify the impact of periodontal condition on gut microbiome, we aim to evaluate the clinical, immunological parameters and the microbiological condition by sequencing of subgingival biofilm and stool samples both before and after non-surgical periodontal treatment with and without antibiotics as adjunct.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Diagnosis of Stage III/IV and grade C Periodontitis
  • Presence of at least 20 teeth
  • Good general health
Exclusion Criteria
  • Pregnant or lactating
  • Were suffering from any other systemic diseases (e.g., cardiovascular, diabetes)
  • Received antimicrobials in the previous 6 months
  • Received a course of periodontal treatment within the last 6 months
  • Were taking long-term anti-inflammatory drugs
  • Smoking habits

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FMUD + AMMetronidazole 400mgOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
FMUD + PlacebosMetronidazole PlaceboOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
FMUD + AMOne-Stage Full Mouth DebridementOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
FMUD + AMAmoxicillin 500mgOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.
FMUD + PlacebosOne-Stage Full Mouth DebridementOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
FMUD + PlacebosAmoxicillin PlaceboOne session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.
Primary Outcome Measures
NameTimeMethod
Change in the oral-gut axis microbiome at 3 monthsBaseline and 90 days

Concentration of bacteria in the subgingival biofilm and stool samples

Secondary Outcome Measures
NameTimeMethod
Change of the baseline relative clinical attachment level at 3 monthsBaseline, 30 days and 90 days

Distance from the bottom of the pocket to the stent margin.

Change of biofilm gene expression on oral microbiome at 3 monthsBaseline and 90 days

RNA-seq of 3 samples FMUD+AM group and validation by quantitative polymerase chain reaction

Change of the baseline inflammatory markers levels in gingival crevicular fluid (pg/uL) and stool samplesBaseline and 90 days

Concentration of cytokines and biomarkers in gingival crevicular fluid and in stool samples

Trial Locations

Locations (1)

University of Campinas, UNICAMP

🇧🇷

Piracicaba, Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath